Literature DB >> 31830541

Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis.

Liuwan Zhao1, Chunyan Gu2, Ye Gan1, Lanlan Shao1, Hongwei Chen3, Hongyan Zhu4.   

Abstract

High recurrence and metastasis of triple-negative breast cancer (TNBC) after operation is a leading cause of breast cancer related death. The pre-metastatic niche (PMN) is an environment in a secondary organ conducive to the metastasis of a primary tumor. Herein, we identify exosomes from autologous breast cancer cells that show effective lung targeting ability. Based on this, we developed the biomimetic nanoparticles (cationic bovine serum albumin (CBSA) conjugated siS100A4 and exosome membrane coated nanoparticles, CBSA/siS100A4@Exosome) to improve drug delivery to the lung PMN. CBSA/siS100A4@Exosome self-assembled nanoparticles formed homogeneous sizes of ~200 nm, protected siRNA from degradation, and showed excellent biocompatibility. Further in vivo studies showed that CBSA/siS100A4@Exosome had a higher affinity toward lung in comparison to the CBSA/siS100A4@Liposome, and exhibited outstanding gene-silencing effects that significantly inhibited the growth of malignant breast cancer cells. Taken together, these results indicate that CBSA/siS100A4@Exosome self-assembled nanoparticles are a promising strategy to suppress postoperative breast cancer metastasis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; CBSA; Exosomes; Pre-metastatic niche; siS100A4

Mesh:

Substances:

Year:  2019        PMID: 31830541     DOI: 10.1016/j.jconrel.2019.12.005

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  60 in total

1.  Students engage in primary literature in molecular biology techniques using an online journal club format.

Authors:  Julia Thom Oxford; Cheryl L Jorcyk
Journal:  Biochem Mol Biol Educ       Date:  2020-10-20       Impact factor: 1.160

2.  Measurement and standardization challenges for extracellular vesicle therapeutic delivery vectors.

Authors:  Bryant C Nelson; Samantha Maragh; Ionita C Ghiran; Jennifer C Jones; Paul C DeRose; Elzafir Elsheikh; Wyatt N Vreeland; Lili Wang
Journal:  Nanomedicine (Lond)       Date:  2020-09-04       Impact factor: 5.307

3.  Engineering Extracellular Vesicles for Cancer Therapy.

Authors:  Christina Nedeva; Suresh Mathivanan
Journal:  Subcell Biochem       Date:  2021

Review 4.  Non-viral vectors for RNA delivery.

Authors:  Yi Yan; Xiao-Yu Liu; An Lu; Xiang-Yu Wang; Lin-Xia Jiang; Jian-Cheng Wang
Journal:  J Control Release       Date:  2022-01-10       Impact factor: 9.776

Review 5.  Exosomal proteins: Key players mediating pre‑metastatic niche formation and clinical implications (Review).

Authors:  Mei Wang; Xinxin Zhao; Feng Huang; Lin Wang; Jiaying Huang; Zheng Gong; Wanjun Yu
Journal:  Int J Oncol       Date:  2021-03-02       Impact factor: 5.650

Review 6.  Plant Exosome-like Nanovesicles: Emerging Therapeutics and Drug Delivery Nanoplatforms.

Authors:  Haseeb Anwar Dad; Ting-Wei Gu; Ao-Qing Zhu; Lu-Qi Huang; Li-Hua Peng
Journal:  Mol Ther       Date:  2020-12-03       Impact factor: 11.454

Review 7.  Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.

Authors:  Mengjiao Zhou; Minjian Yuan; Meng Zhang; Chenyi Lei; Omer Aras; Xiaohong Zhang; Feifei An
Journal:  Eur J Med Chem       Date:  2021-09-04       Impact factor: 7.088

Review 8.  Extracellular vesicles as delivery systems at nano-/micro-scale.

Authors:  Peiwen Fu; Jianguo Zhang; Haitao Li; Michael Mak; Wenrong Xu; Zhimin Tao
Journal:  Adv Drug Deliv Rev       Date:  2021-08-03       Impact factor: 15.470

Review 9.  Nanodelivery of STING agonists against cancer and infectious diseases.

Authors:  Jiarong Zhou; Christian J Ventura; Ronnie H Fang; Liangfang Zhang
Journal:  Mol Aspects Med       Date:  2021-08-02

10.  Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles.

Authors:  Aixue Li; Yunan Zhao; Yixiu Li; Liangdi Jiang; Yongwei Gu; Jiyong Liu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.